{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T01:47:02Z","timestamp":1791424022865,"version":"4.3.3"},"reference-count":54,"publisher":"Informa Healthcare","issue":"5","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Current Medical Research and Opinion"],"published-print":{"date-parts":[[2009,5,1]]},"DOI":"10.1185\/03007990902869169","type":"journal-article","created":{"date-parts":[[2009,4,14]],"date-time":"2009-04-14T13:54:31Z","timestamp":1239717271000},"page":"1273-1284","source":"Crossref","is-referenced-by-count":21,"title":["Cost-effectiveness of insulin detemir compared to NPH insulin for type 1 and type 2 diabetes mellitus in the Canadian payer setting: modeling analysis"],"prefix":"10.1185","volume":"25","author":[{"given":"Sandra L.","family":"Tunis","sequence":"first","affiliation":[{"name":"IMS Consulting Services, Falls Church, VA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael E.","family":"Minshall","sequence":"additional","affiliation":[{"name":"formerly, IMS-Health, Falls Church, VA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher","family":"Conner","sequence":"additional","affiliation":[{"name":"Novo Nordisk, Princeton, NJ, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John I.","family":"McCormick","sequence":"additional","affiliation":[{"name":"McKesson Canada, Toronto, ON, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jovana","family":"Kapor","sequence":"additional","affiliation":[{"name":"Novo Nordisk, Mississauga, ON, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean-Fran\u00e7ois","family":"Yale","sequence":"additional","affiliation":[{"name":"McGill University, Montreal, Quebec, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Danielle","family":"Groleau","sequence":"additional","affiliation":[{"name":"Novo Nordisk, Mississauga, ON, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"3197","published-online":{"date-parts":[[2009,4,8]]},"reference":[{"key":"CIT0001","unstructured":"Health Canada. Diabetes in Canada, 2nd Edition. Health Canada 2002. Available at: URL: http:\/\/www.phac.aspc.gc.ca\/publicat\/dic-dac2\/pdf\/dic-dac2_en.pdf"},{"key":"CIT0002","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.322.7299.1389"},{"key":"CIT0003","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199309303291401"},{"key":"CIT0004","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(98)07037-8"},{"key":"CIT0005","first-page":"i","volume":"27","author":"Canadian Diabetes Association","year":"2003","journal-title":"Can J Diabetes"},{"key":"CIT0006","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra040832"},{"key":"CIT0007","doi-asserted-by":"publisher","DOI":"10.1007\/s00125-005-0108-0"},{"key":"CIT0008","unstructured":"Current Utilization of Insulin Products in Canada. Current Utilization and Practice Analysis. Canadian Optimal Medication Prescribing and Utilization Service (COMPUS), 2008"},{"key":"CIT0009","unstructured":"An Economic Evaluation of Insulin Analogues for the Treatment of Patients with Type 1 and Type 2 Diabetes Mellitus in Canada. Canadian Optimal Medication Prescribing and Utilization Service (COMPUS);2008"},{"key":"CIT0010","doi-asserted-by":"publisher","DOI":"10.1185\/030079904X5661"},{"key":"CIT0011","doi-asserted-by":"publisher","DOI":"10.1007\/BF02850126"},{"key":"CIT0012","first-page":"766","volume":"14","author":"Brixner DI","year":"2008","journal-title":"Am J Manage Care"},{"key":"CIT0013","doi-asserted-by":"publisher","DOI":"10.1185\/030079904X2033"},{"key":"CIT0014","doi-asserted-by":"publisher","DOI":"10.1185\/030079906X115757"},{"key":"CIT0015","unstructured":"National Institute for Clinical Excellence (NICE). Guidance on the Use of Long-Acting Insulin Analogues for the Treatment of Diabetes - Insulin Glargine. 2002 Jan 12. Technology Appraisal Guidance - No. 53"},{"key":"CIT0016","doi-asserted-by":"publisher","DOI":"10.1007\/s00125-007-0911-x"},{"key":"CIT0017","doi-asserted-by":"publisher","DOI":"10.1038\/sj.ijo.0802749"},{"key":"CIT0018","doi-asserted-by":"publisher","DOI":"10.1111\/j.1464-5491.2007.02407.x"},{"key":"CIT0019","doi-asserted-by":"publisher","DOI":"10.2337\/diacare.27.5.1081"},{"key":"CIT0020","doi-asserted-by":"publisher","DOI":"10.1111\/j.1463-1326.2007.00804.x"},{"key":"CIT0021","doi-asserted-by":"publisher","DOI":"10.2337\/diacare.27.9.2262"},{"key":"CIT0022","doi-asserted-by":"publisher","DOI":"10.1185\/030079904X1980"},{"key":"CIT0023","doi-asserted-by":"publisher","DOI":"10.1185\/030079904X2006"},{"key":"CIT0024","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa052187"},{"key":"CIT0025","unstructured":"Visible Minority Population, by Age Group (2001 Census). Statistics Canada, 2005"},{"key":"CIT0026","unstructured":"Centers for Disease Control and Prevention (CDC). National Center for Health Statistics (NCHS). National Health and Nutrition Examination Survey (NHANES). U.S. Department of Health and Human Services 2000"},{"key":"CIT0027","unstructured":"O'Reilly D, Hopkins R, Blackhouse G, et al. Development of an Ontario Diabetes Economic Model (ODEM) and Application to a Multidisciplinary Primary Care Diabetes Management Program. Hamilton, Ontario, Canada: Program for Assessment of Technology in Health (PATH), 2006"},{"key":"CIT0028","doi-asserted-by":"publisher","DOI":"10.1016\/S0002-9149(98)00583-9"},{"key":"CIT0029","doi-asserted-by":"publisher","DOI":"10.1016\/S0025-6196(12)62535-X"},{"key":"CIT0030","doi-asserted-by":"publisher","DOI":"10.2337\/diacare.23.6.754"},{"key":"CIT0031","doi-asserted-by":"publisher","DOI":"10.1001\/archinte.1992.00400150120022"},{"key":"CIT0032","doi-asserted-by":"publisher","DOI":"10.2337\/diacare.26.8.2300"},{"key":"CIT0033","unstructured":"Nova Scotia Pharmacy: Annual Pricing, 2007"},{"key":"CIT0034","unstructured":"Nova Scotia Pharmacy: Pricing with a 30-day Supply Assumption, 2007"},{"key":"CIT0035","unstructured":"Nova Scotia. Nova Scotia Optometrist Fees. Nova Scotia, 2007"},{"key":"CIT0036","unstructured":"Nova Scotia. Nova Scotia Podiatrist Fees. Nova Scotia, 2007"},{"key":"CIT0037","doi-asserted-by":"publisher","DOI":"10.2165\/00019053-200220001-00004"},{"key":"CIT0038","doi-asserted-by":"publisher","DOI":"10.1186\/1472-6963-3-7"},{"key":"CIT0039","doi-asserted-by":"publisher","DOI":"10.1185\/030079905X65349"},{"key":"CIT0040","unstructured":"Alberta Physician Fee Schedule. Alberta Physician Fee Schedule. Province of Alberta, Ministry of Health 2004. Available at: URL: http:\/\/www.web.ab.ca\/pdfs\/providers\/WCB_Fee_Schedule_Alberta_Physicians.pdf"},{"key":"CIT0041","unstructured":"Manns B, Johnson JA, Taub K et al. Quality of life in patients with end-stage renal disease over time: the impact of dialysis modality and other important determinants. Edmonton, Alberta, Canada: Institute of Pharmaco-Economics, 2002. Report No. 02-05"},{"key":"CIT0042","unstructured":"Manns B, Tonelli M, Shrive F et al. Sevelamer in patients with end-stage renal disease: a systematic review and economic evaluation. Canadian Agency for Drugs and Technologies in Health, 2006"},{"key":"CIT0043","unstructured":"Health Costing in Alberta: 2006 Annual Report. Edmonton, Alberta, Canada: Alberta Health and Wellness, 2008"},{"key":"CIT0044","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2261-5-14"},{"key":"CIT0045","unstructured":"Royal Bank of Canada, 2007. Bank of Canada, Inflation Calculator, 2008. Available at: URL: http:\/\/www.bankofcanada.ca\/en\/rates\/inflation_calc.html"},{"key":"CIT0046","unstructured":"Canadian Agency for Drugs and Technologies in Health (CADTH). Guidelines for the Economic Evaluation of Health Technologies: Canada, 3rd edn. Ottawa, Ontario, Canada: CADTH Publications, 2006"},{"key":"CIT0047","doi-asserted-by":"publisher","DOI":"10.1177\/0272989X0002000308"},{"key":"CIT0048","first-page":"473","volume":"146","author":"Laupacis A","year":"1992","journal-title":"Tentative guidelines for using clinical and economic evaluations. Can Med Assoc J"},{"key":"CIT0049","first-page":"186","volume":"29","author":"Leiter LA","year":"2005","journal-title":"Can J Diabetes"},{"key":"CIT0050","doi-asserted-by":"publisher","DOI":"10.1002\/dmrr.796"},{"key":"CIT0051","doi-asserted-by":"publisher","DOI":"10.1016\/j.pec.2007.05.003"},{"key":"CIT0052","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0802743"},{"key":"CIT0053","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0802987"},{"key":"CIT0054","doi-asserted-by":"publisher","DOI":"10.2337\/dc08-9026"}],"container-title":["Current Medical Research and Opinion"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1185\/03007990902869169","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,8,29]],"date-time":"2020-08-29T01:56:32Z","timestamp":1598666192000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.1185\/03007990902869169"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,4,8]]},"references-count":54,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2009,5,1]]}},"alternative-id":["10.1185\/03007990902869169"],"URL":"https:\/\/doi.org\/10.1185\/03007990902869169","relation":{},"ISSN":["0300-7995","1473-4877"],"issn-type":[{"value":"0300-7995","type":"print"},{"value":"1473-4877","type":"electronic"}],"subject":[],"published":{"date-parts":[[2009,4,8]]}}}